Merck Makes Deal to Develop Schizophrenia Drug
15688
Merck agreed to pay a Swiss company, Addex Pharmaceuticals, as much as $702 million to help develop a new schizophrenia drug.
400965
Medarex's partner advances one of its compounds into later stage clinical testing.
583185
Consolidation in Europe's drugs  sector gathered steam on Thursday as Germany's Merck unveiled a  $13.3-billion deal to buy Europe's top biotech firm Serono, and  Denmark's Nycomed won the drugs unit of Altana.
79075
Eli Lilly pushed Zyprexa, a drug for schizophrenia and bipolar disorder, as a treatment for older patients with dementia, according to marketing materials.
130777
The first new class of drugs in more than a decade for treating schizophrenia worked at least as well in a clinical trial as standard medications, a study released Sunday showed.
430243
An experimental drug lessened schizophrenia symptoms without the serious side effects of current treatments.
203734
GlaxoSmithKline Plc  has signed a  drug discovery deal with U.S. biotech firm ChemoCentryx  potentially worth up to $1.5 billion in milestone payments and  research funding to the privately owned group.
646011
Drugmaker Merck &amp; Co., under financial siege since pulling its top painkiller Vioxx off the market in September, said Monday it has adopted a plan that
265877
FRANKFURT/ZURICH  - German drugmaker Merck KGaA   MRCG.DE unveiled a surprise 16.6-billion-Swiss franc ($13.3   billion) deal to buy Swiss biotech firm Serono on Thursday,   creating a new force in European pharmaceuticals.
218831
FRANKFURT/ZURICH  - German drugmaker Merck KGaA   MRCG.DE unveiled a surprise $13.3 billion deal to buy   Europe's biggest biotech firm Serono SEO.VX on Thursday,   creating a new force in European pharmaceuticals.
41870
A drug developed by Merck helps people lose weight by inducing an reverse-marijuana effect: decreasing appetite.
145102
Scientists find the answer to stopping the virus might be right under their noses -- generic antipsychotic medications. By Serena Gordon.
138327
Swiss biotech company Addex Pharmaceuticals SA  could receive more than $700 million from Merck & Co Inc  for a licensing deal on its ADX63365 drug for schizophrenia, it said on Thursday.
274636
Merck and Schering-Plough get together again.
96120
An experimental treatment for schizophrenia produced fewer worrisome side effects compared with drugs currently in use, its makers said on Wednesday.
624821
NEW YORK -- Swiss biotech firm Serono SA, which earlier Thursday agreed to sell a majority stake in the company to German drugmaker Merck KGaA for $13.31 billion, said its oral cladribine treatment for multiple sclerosis has received "fast-track" status from the U.S. Food and Drug Administration.
138698
Another schizophrenia drug from the company shows promise in a clinical trial.